Skin Cancer

The Netherlands' first user of Elekta's Esteya Electronic Brachytherapy

On March 3, Radiotherapy Group clinicians at Ziekenhuis Gelderse Vallei (Ede, the Netherlands) used their Esteya electronic brachytherapy system for the first time to treat a 73-year-old male patient with a nodular basal cell carcinoma on his nose. Esteya is a form of high dose rate (HDR) brachytherapy that applies high-precision radiotherapy directly to the cancer site, minimizing radiation to surrounding healthy tissues. On March 16, the Netherland's Radiotherapy Group (Radiotherapiegroep) followed up this first use of Esteya at one of its locations in Ziekenhuis Gelderse Vallei by treating five additional patients with six lesions - five on the nose and one on the leg.

Photo: The Netherlands first user of Elektas Esteya Electronic Brachytherapy

"This first patient had previous surgery for skin cancer on his shoulder that had left a visible scar and his brother had undergone surgery for skin cancer on his nose, so he knew what the outcome might be with surgery," says Ronald Keus, MD, a staff radiation oncologist with the Radiotherapy Group. "He declined surgery and opted for Esteya electronic brachytherapy because he knew the treatment should provide much better cosmetic results."

Besides cosmetic concerns, most other candidates for Esteya are selected due to contraindications for surgery, including the use of therapeutic anticoagulants and cardiac risks, he adds.

Esteya adds an attractive treatment alternative for Radiotherapy Group, which for decades has been using linear accelerator-based treatment for skin cancer patients. "Esteya is especially suitable for smaller, superficial lesions," Dr. Keus says. "With electron treatments on a linear accelerator, the beam can be too deep and large to avoid exposing healthy tissues. With a sharper dose fall-off, Esteya enables us to treat lesions up to a few centimeters in size at a depth down to five millimeters. In addition, for all Esteya patients the treatment schedule is just six visits [6 X 7 Gy], two fractions per week for just a few minutes per treatment. The conventional radiotherapy course would be 20 separate visits."

The Esteya treatment set up and the therapy itself has been appealing to patients. "The therapy is staged in a small room with a comfortable chair and patients tell us that the treatment is quick and painless without much hassle at all," he adds. "From an operational standpoint, treating with Esteya requires less staff and it's a dedicated machine that is cost-effective to operate."

With a second Esteya system set to begin treating patients in Radiotherapy Group's center in Deventer in about eight weeks, Dr. Keus predicts they will reach a treatment volume of at least 60 patients each year.


To spur interest in Esteya, Radiotherapy Group organized a symposium to introduce Esteya for 20-30 dermatologists in the area on Monday, March 21. "Esteya electronic brachytherapy is a simple and elegant treatment that provides good local control and good cosmesis for small skin cancer lesions," he says. "We are happy to be able to offer our patients this alternative approach. We hope the symposium on Esteya convinces the dermatologists in our regional neighboring hospitals to offer this option to the large numbers of patients they see."


Source: Elekta

23.03.2016

Read all latest stories

Related articles

Oncology

Nanotechnology supports treatment of malignant melanoma

Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology. This report researchers from the Swiss Nanoscience Institute, the…

Tackling mobile tumours

Precision radiotherapy with 4D imaging

Radiotherapy always encounters particular challenges when a tumour is ‘mobile’. This is when radiotherapy must be carried out over several weeks. Within that period the tumour position, shape and…

Immunotherapy

Toward an “ultra-personalized” therapy for melanoma

With new immunotherapy treatments for melanoma, recovery rates have risen dramatically – in some cases to around 50%. But they could be much higher. A new study led by researchers at the Weizmann…

Related products

Accessories / Complementary systems

Alliance Medical - Flexible diagnostic imaging services

Alliance Medical Interim Solutions

Multi-modality suites

Canon - Infinix-i 4D CT

Canon Europa NV

Single Plane

Canon - Infinix-i Core

Canon Europa NV

Single Plane

Canon - Infinix-i Core+ (Version I)

Canon Europa NV